Table 1.
Clinical and demographic characteristics of participants who reported receiving chemotherapy in the Detroit Research on Cancer Survivors (ROCS) cohort stratified by whether they reported prevalent chemotherapy-induced peripheral neuropathy
| Total |
Prevalent CIPN1 |
p-value* | ||||
|---|---|---|---|---|---|---|
| N | % | Yes | No | Row % | ||
|
| ||||||
| 1034 | 704 | 330 | 68% | |||
| Demographics | ||||||
| Gender | < .001 | |||||
| Male | 237 | 22.9 | 134 | 103 | 57% | |
| Female | 797 | 77.1 | 570 | 227 | 72% | |
| Age at Diagnosis | < .001 | |||||
| ≤50 | 255 | 24.7 | 198 | 57 | 78% | |
| 51–64 | 508 | 49.1 | 350 | 158 | 69% | |
| 65 + | 271 | 26.2 | 156 | 115 | 58% | |
| mean (std) | 57.1 (10.9) | 55.8 (10.8) | 59.9 (10.4) | |||
| median (range) | 58 (27–79) | 57 (27–79) | 61 (27–79) | |||
| Marital status | 0.011 | |||||
| Married or equivalent | 347 | 33.8 | 232 | 115 | 67% | |
| Widowed | 113 | 11.0 | 71 | 42 | 63% | |
| Divorced or separated | 278 | 27.1 | 211 | 67 | 76% | |
| Never married | 288 | 28.0 | 186 | 102 | 65% | |
| Educational attainment | 0.011 | |||||
| Less than High School | 89 | 8.7 | 52 | 37 | 58% | |
| High school/GED | 254 | 24.9 | 159 | 95 | 63% | |
| Some college/2-year degree | 403 | 39.5 | 281 | 122 | 70% | |
| Four-year college degree | 120 | 11.8 | 86 | 34 | 72% | |
| Graduate/professional degree | 154 | 15.1 | 117 | 37 | 76% | |
| Cancer characteristics | ||||||
| Cancer site | < .001 | |||||
| Breast | 599 | 57.9 | 444 | 155 | 74% | |
| Colorectal | 206 | 19.9 | 163 | 43 | 79% | |
| Lung | 177 | 17.1 | 79 | 98 | 45% | |
| Prostate | 52 | 5.0 | 18 | 34 | 35% | |
| SEER summary stage | 0.005 | |||||
| Local | 342 | 33.1 | 231 | 111 | 68% | |
| Regional | 498 | 48.2 | 358 | 140 | 72% | |
| Distant | 188 | 18.2 | 111 | 77 | 59% | |
| Medical History | ||||||
| BMI at enrollment | 0.003 | |||||
| Underweight/normal weight | 231 | 22.7 | 143 | 88 | 62% | |
| Overweight | 322 | 31.5 | 208 | 114 | 65% | |
| Obese | 469 | 45.9 | 344 | 125 | 73% | |
| Mean (std) | 30.3 (7.2) | 30.8 (7.4) | 29.2 (6.6) | |||
| Median (range) | 29.4 (14.6–66.2) | 29.9 (14.6–66.2) | 28.5 (15.8–51.6) | |||
| Comorbidity count | 0.946 | |||||
| None | 94 | 9.2 | 62 | 32 | 66% | |
| 1 | 206 | 20.3 | 145 | 61 | 70% | |
| 2 | 222 | 21.8 | 150 | 72 | 68% | |
| 3 | 170 | 16.7 | 115 | 55 | 68% | |
| 4 or more | 325 | 32.0 | 221 | 104 | 68% | |
| Diabetes mellitus | 0.377 | |||||
| Yes | 224 | 21.8 | 147 | 77 | 66% | |
| No | 806 | 78.3 | 554 | 252 | 69% | |
| Thyroid problem | 0.508 | |||||
| Yes | 113 | 11.0 | 80 | 33 | 71% | |
| No | 917 | 89.0 | 621 | 296 | 68% | |
| Arthritis | 0.571 | |||||
| Yes | 419 | 40.7 | 281 | 138 | 67% | |
| No | 611 | 59.3 | 420 | 191 | 69% | |
| Smoker (≥ 100 cigs lifetime) | 0.004 | |||||
| Yes | 513 | 49.9 | 328 | 185 | 64% | |
| No | 515 | 50.1 | 372 | 143 | 72% | |
| Alcohol Use (in the past 4 weeks) | 0.184 | |||||
| Yes | 395 | 38.4 | 278 | 117 | 70% | |
| No | 634 | 61.6 | 421 | 213 | 66% | |
| Diagnosis to enrollment time (months) | 0.289 | |||||
| Mean (std) | 23.0 (18.4) | 23.1 (18.2) | 22.8 (18.8) | |||
| Median (range) | 16 (2–84) | 16 (2–82) | 16 (2–84) | |||
*
p-values based on chi-square testing, Fisher’s exact test for small cell counts and p-trend for ordinal values
CIPN prevalence was defined by the presence of self-reported PN symptoms (pain, numbness, or tingling in the hands or feet) at any time since starting chemotherapy or worsening of any prior PN symptoms after chemotherapy administration